Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer

European Urology

Volumn 49, Issue 4, 2006, Pages 698-703

  Schrier, B Ph ^a,b   Peters, M ^a   Barentsz, J O ^a   Witjes, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Bladder cancer; Chemotherapy; MR imaging; Transitional cell carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DRUG TOLERANCE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TIME; TRANSURETHRAL RESECTION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CONTRAST MEDIA; DOXORUBICIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 33644865630     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.01.022     Document Type: Article

References (23)

1. The Netherlands Cancer Registry. Urological tumours in the Netherlands 1989-1996. Visser O, Schouten LJ, van Dijck JAAM, Coebergh JWW. Utrecht: 1999, pp. 25-7.
2. R. Lee, and M.J. Droller The natural history of bladder cancer: Implications for therapy Urol Clin North Am 27 2000 1 13
3. L.H. Sobin, and Ch. Wittekind TNM classification of malignant tumours 5th ed. 1997 Wiley-Liss Inc New York pp. 187-9
4. J.P. Stein, and D.G. Skinner The role of lymphadenectomy in high-grade invasive bladder cancer Urol Clin North Am 32 2005 187 197
5. D.G. Skinner, and G. Lieskovsky Management of invasive and high-grade bladder cancer D.G. Skinner G. Lieskovsky Diagnosis and Management of Genitourinary Cancer 1988 WB Saunders Philadelphia 295 312
6. C.N. Sternberg, A. Yagoda, H.I. Scher, R.C. Watson, N. Geller, and H.W. Herr Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse Cancer 64 1989 2448 2458
7. J.P. Connor, C.A. Olsson, M.C. Benson, F. Rapoport, and I.S. Sawczuk Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern Urology 34 1989 353 356
8. I. Tannock, M. Gospodarowicz, J. Connolly, and M. Jewett M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience J Urol 142 1989 289 292
9. K.L. Verstraete, H.J. Van der Woude, P.C. Hogendoorn, Y. De-Deene, M. Kunnen, and J.L. Bloem Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications J Magn Reson Imaging 6 1996 311 321
10. J.O. Barentsz, G.J. Jager, P.B.J. van Viersen, J.A. Witjes, S.P. Strijk, and H. Peters Staging urinary bladder cancer after transurethral biopsy: the value of fast dynamic contrast-enhanced MR imaging Radiology 201 1996 185 193
11. G. Ranieri, and G. Gasparini Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy Curr Drug Targets Immune Endocr Discord 1 2001 241 253
12. P. Lang, M. Vahlensieck, K.K. Matthay, J.O. Johnston, W. Rosenau, and C.A. Gooding Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography Med Pediatr Oncol 26 1996 329 333
13. T.J. Passe, D.A. Bluemke, and S.S. Siegelman Tumor angiogenesis: tutorial on implications for imaging Radiology 203 1997 593 600
14. R. De Wit New developments in chemotherapy for metastasized bladder cancer Ned Tijdschr Geneeskd 145 2001 2412 2417
15. J.A. Witjes, M. Wullink, G.O. Oosterhof, and P. de Mulder Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma Eur Urol 31 1997 414 419
16. D. Pectasides, M. Pectasides, and M. Nikolaou Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: Literature review Eur Urol 48 2005 60 68
17. T.A. Splinter, H.I. Scher, L. Denis, R. Bukowski, S. Simon, I. Klimberg European Organization for Research on Treatment of Cancer - Genitourinary Group The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer J Urol 147 1992 606 608
18. H.W. Herr, D.F. Bajorin, and H.I. Scher Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome J Clin Oncol 16 1998 1298 1301
19. H. Herr, S.M. Donat, and D.F. Bajorin Post chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer J Urol 165 2001 811 814
20. H. Von der Maase, S.W. Hansen, J.T. Roberts, L. Dogliotti, T. Oliver, and M.J. Moore Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 17 2000 3068 3077
21. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systemic review and meta-analysis Lancet 361 2003 1927 1934
22. E. Winquist, T.S. Kirchner, and R. Segal Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis J Urol 171 2004 561 569
23. C. Sternberg Current perspectives in muscle invasive bladder cancer Eur J Cancer 38 2002 460 467